Jasper Therapeutics, Inc. (JSPR) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Jasper Therapeutics reported revenue of $42.2M. Net income was -$75.8M (a -179.4% net margin), or -$3.95 per diluted share. Gross margin was -98.5% and operating margin was -198.5%. Operating activities generated -$77.2M of cash, leaving -$77.2M of free cash flow. At fiscal year end, Jasper Therapeutics held $35.8M in total assets against $31.6M in total liabilities, including $28.7M of cash and equivalents.
Open the full interactive Jasper Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Jasper Therapeutics Key Stats
| Share Price | $0.50 |
|---|---|
| Market Cap | $14.2M |
| 52-Week Range | $0.34 – $2.60 |
| Shares Outstanding | 28.7 million (basic, 2026 Q2) |
Jasper Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $42.2M |
| Gross Profit | — | — | — | — | — | -$41.6M |
| Operating Income | -$935,400 | -$36.8M | -$51.2M | -$68.9M | -$76.2M | -$83.9M |
| Pre-Tax Income | -$552,250 | -$30.6M | -$37.7M | -$64.5M | -$71.3M | -$75.8M |
| Income Tax | $38,451 | — | — | — | $2,000 | — |
| Net Income | -$590,701 | -$30.6M | -$37.7M | -$64.5M | -$71.3M | -$75.8M |
| Diluted EPS | -$0.59 | -$26.90 | -$10.30 | -$6.18 | -$4.89 | -$3.95 |
Jasper Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $9.8M | $32.4M | $7.3M | $5.6M |
| Net Income | -$18.7M | -$9.1M | -$1.2M | -$2.8M |
| Diluted EPS | -$1.13 | -$0.47 | -$0.04 | -$0.10 |
Jasper Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $770,114 | $84.7M | $38.2M | $86.9M | $71.6M | $28.7M |
| Current Assets | $921,642 | $87.8M | $41.7M | $88.9M | $75.8M | $34.6M |
| Total Assets | $101.3M | $93.7M | $48.4M | $94.9M | $79.9M | $35.8M |
| Current Liabilities | $269,451 | $8.0M | $7.1M | $12.4M | $15.2M | $13.2M |
| Total Liabilities | $3.8M | $24.1M | $12.4M | $16.5M | $18.2M | $31.6M |
| Shareholders' Equity | $5.0M | $69.5M | $36.0M | $78.4M | $61.7M | $4.2M |
Jasper Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$640,984 | -$33.7M | -$45.9M | -$52.1M | -$62.6M | -$77.2M |
| Cash From Investing | $198,343 | -$2.4M | -$576,000 | -$267,000 | -$532,000 | $5,000 |
| Cash From Financing | — | $101.0M | $55,000 | $101.0M | $47.9M | $34.2M |
| Free Cash Flow | — | — | — | -$52.1M | -$62.6M | -$77.2M |
Figures from Jasper Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Jasper Therapeutics financials page for every line item.
Jasper Therapeutics Company Profile
| Ticker | JSPR |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Redwood City, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001788028 |
Frequently Asked Questions
What was Jasper Therapeutics' revenue in fiscal 2025?
Jasper Therapeutics (JSPR) reported revenue of $42.2M for fiscal 2025.
What is Jasper Therapeutics' annual revenue history?
Jasper Therapeutics' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $42.2M.
What was Jasper Therapeutics' net income in fiscal 2025?
Jasper Therapeutics reported net income of -$75.8M for fiscal 2025.
What was Jasper Therapeutics' earnings per share (EPS) in fiscal 2025?
Jasper Therapeutics' diluted EPS was -$3.95 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Jasper Therapeutics generate in fiscal 2025?
Jasper Therapeutics generated -$77.2M of free cash flow in fiscal 2025.
What was Jasper Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Jasper Therapeutics reported revenue of $5.6M.
How many shares of Jasper Therapeutics are outstanding?
Jasper Therapeutics reported a weighted average of 28.7 million basic shares outstanding in 2026 Q2.
What is Jasper Therapeutics' market cap?
Based on its latest closing price, Jasper Therapeutics (JSPR) has a market capitalization of about $14.2M.
When does Jasper Therapeutics' fiscal year end?
Jasper Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Jasper Therapeutics headquartered?
Jasper Therapeutics lists its business address in Redwood City, California in its SEC filings.
Jasper Therapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →